Synthesis of an undecasaccharide featuring an oligomannosidic heptasaccharide and a bacterial Kdo-lipid A backbone for eliciting neutralizing antibodies to mammalian oligomannose on the HIV-1 envelope spike. Trattnig N, Blaukopf M, Bruxelle JF, Pantophlet R, Kosma P. J Am Chem Soc. 2019 Apr 22. doi: 10.1021/jacs.9b02872. [Epub ahead of print]

Comparative antigenicity of thiourea- and adipic amide linked neoglycoconjugates containing modified oligomannose epitopes for the carbohydrate-specific anti-HIV antibody 2G12. Trattnig N, Mayrhofer P, Kunert R, Mach L, Pantophlet R, Kosma P. Bioconjug Chem. 2019 Jan 16;30(1):70-82. doi: 10.1021/acs.bioconjchem.8b00731. Epub 2018 Dec 28.


Synthesis of a Pentasaccharide Fragment Related to the Inner Core Region of Rhizobial and Agrobacterial Lipopolysaccharides. Trattnig N, Farcet JB, Gritsch P, Christler A, Pantophlet R, Kosma P. J Org Chem. 2017 Dec 1;82(23):12346-12358. doi: 10.1021/acs.joc.7b02172. Epub 2017 Oct 26.

Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. Pantophlet R, Trattnig N, Murrell S, Lu N, Chau D, Rempel C, Wilson IA, Kosma P. Nat Commun. 2017 Nov 17;8(1):1601. doi: 10.1038/s41467-017-01640-y.


Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual. Khan L, Makhdoomi MA, Kumar S, Nair A, Andrabi R, Clark BE, Auyeung K, Bhattacharya J, Vajpayee M, Wig N, Pantophlet R, Luthra K. PLoS One. 2015 May 11;10(5):e0125575. doi: 10.1371/journal.pone.0125575. eCollection 2015.

Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. Stanfield RL, De Castro C, Marzaioli AM, Wilson IA, Pantophlet R. Glycobiology. 2015 Apr;25(4):412-9. doi: 10.1093/glycob/cwu123. Epub 2014 Nov 7.


The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. Manhas S, Chau D, Rempel C, Clark BE, Auyeung K, Pantophlet R. Virology. 2014 Aug;462-463:98-106. doi: 10.1016/j.virol.2014.05.034. Epub 2014 Jun 25.


Pantophlet, R. (ed.). HIV Glycans in Infection and Immunity. New York: Springer, 2013.

2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies. Doores KJ, Huber M, Le KM, Wang SK, Doyle-Cooper C, Cooper A, Pantophlet R, Wong CH, Nemazee D, Burton DR. J Virol. 2013 Feb;87(4):2234-41. doi: 10.1128/JVI.02820-12. Epub 2012 Dec 5.


A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV-neutralizing antibody 2G12 as a template for vaccine design. Clark BE, Auyeung K, Fregolino E, Parrilli M, Lanzetta R, De Castro C, Pantophlet R. Chem Biol. 2012 Feb 24;19(2):254-63. doi: 10.1016/j.chembiol.2011.12.019.

Complex binding sites made to order. Scott JK, Pantophlet R, Craig L. Nat Biotechnol. 2012 Feb 8;30(2):154-5. doi: 10.1038/nbt.2118. No abstract available.

An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site. Ahmed FK, Clark BE, Burton DR, Pantophlet R. Vaccine. 2012 Jan 20;30(5):922-30. doi: 10.1016/j.vaccine.2011.11.089. Epub 2011 Dec 4.


Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, Chakauya E, O’Keefe BR, Chikwamba R, Morris L. J Virol. 2011 Sep;85(17):9039-50. doi: 10.1128/JVI.02675-10. Epub 2011 Jun 22.


Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR. Chem Biol. 2010 Apr 23;17(4):357-70. doi: 10.1016/j.chembiol.2010.03.012.

Antibody epitope exposure and neutralization of HIV-1. Pantophlet R. Curr Pharm Des. 2010;16(33):3729-43. Review.